All In MedTech

Device Trial Radar · NCT05432232

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Mar 23, 2023

Primary completion

Dec 28, 2024

Study completion Jun 6, 2025

Sponsor

Lead sponsor
HistoSonics, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 27, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the technical success and safety profile of the HistoSonics Investigational System for the treatment of primary solid renal tumors.

Conditions

  • Renal Cancer
  • Tumor, Solid
  • Kidney Cancer
  • Tumor
  • Tumor, Benign
  • Kidney Neoplasms

Interventions

  • HistoSonics Investigational SystemDevice

    The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness: Technical SuccessTime frame: Up to 36 hours after the index procedure
  2. Primary Safety: Freedom From Index Procedure Related Major ComplicationsTime frame: 30 days Post-Index Procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.